Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.78 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.61 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15976152 | 0.90 | BACE1 (0.76) | BACE1BACE2PSEN1PSEN2APH1B | |
| Formic Acid SCHEMBL12478650 | 0.88 | BACE1 (0.72) | BACE1BACE2PSEN1PSEN2APH1B | |
| Formic Acid SCHEMBL12478656 | 0.88 | BACE1 (0.72) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL360390 | 0.87 | BACE1 (1.00) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL2595368 | 0.87 | BACE1 (1.00) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL15976154 | 0.87 | BACE1 (0.79) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL2592926 | 0.85 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL360702 | 0.85 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL2590343 | 0.85 | BACE1 (0.86) | BACE1BACE2APP | |
| SCHEMBL2590338 | 0.85 | BACE1 (0.86) | BACE1BACE2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323469-A1 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE1, BACE2, PSEN2 | BACE1 1/4885BACE2 2/4885PSEN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.